1998
DOI: 10.1016/s0003-4975(98)00507-4
|View full text |Cite
|
Sign up to set email alerts
|

Recovery from end-stage ischemic cardiomyopathy during long-term LVAD support

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
16
0

Year Published

2002
2002
2011
2011

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 18 publications
(18 citation statements)
references
References 5 publications
2
16
0
Order By: Relevance
“…Five days after ex vivo delivery of 2ϫ10 11 total viral particles (TVP) of Adv-␤Gal, the transgene was robustly expressed in the transplanted heart, as confirmed by histological galactosidase staining ( Figure 3A). Expression of Adv-␤ 2 AR was dose-dependent, and both 1ϫ10 11 (1ϫ) and 2ϫ10 11 (2ϫ) TVP significantly increased ␤AR density, with the 2ϫ dose increasing it to 511.6Ϯ101.5 fmol/mg membrane protein (nϭ4).…”
Section: Transgene Expressionmentioning
confidence: 81%
See 1 more Smart Citation
“…Five days after ex vivo delivery of 2ϫ10 11 total viral particles (TVP) of Adv-␤Gal, the transgene was robustly expressed in the transplanted heart, as confirmed by histological galactosidase staining ( Figure 3A). Expression of Adv-␤ 2 AR was dose-dependent, and both 1ϫ10 11 (1ϫ) and 2ϫ10 11 (2ϫ) TVP significantly increased ␤AR density, with the 2ϫ dose increasing it to 511.6Ϯ101.5 fmol/mg membrane protein (nϭ4).…”
Section: Transgene Expressionmentioning
confidence: 81%
“…Expression of Adv-␤ 2 AR was dose-dependent, and both 1ϫ10 11 (1ϫ) and 2ϫ10 11 (2ϫ) TVP significantly increased ␤AR density, with the 2ϫ dose increasing it to 511.6Ϯ101.5 fmol/mg membrane protein (nϭ4). This represents Ͼ8 times the value measured in control hearts ( Figure 3B; PϽ0.005).…”
Section: Transgene Expressionmentioning
confidence: 99%
“…All the studies assessed firstgeneration devices with one case report of the Abiomed LVAD, 104 one case report of the HeartMate LVAD, 105 one case report of the Novacor LVAD 106 , two case reports of the Thoratec LVAD, 107,108 and two case series evaluations of the Toyobo LVAD. 109,110 There were no studies of second-generation devices included in the systematic review.…”
Section: Quantity Of Researchmentioning
confidence: 99%
“…A case study reported survival of one patient supported with a Novacor LVAD until recovery of heart function ( Table 24 and Appendix 20). 106 The 54-year-old man with cardiac failure refractory to medical therapies and contraindicated to heart transplant was well enough to be transferred to a partial outpatient status 6 weeks after implant and 3 months later was successfully weaned from the device. The patient was discharged home after 6 weeks and was alive and well at 6 months follow-up.…”
Section: First-generation Lvadsmentioning
confidence: 99%
See 1 more Smart Citation